NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company
18 Décembre 2023 - 2:30PM
NightHawk Biosciences (NYSE American:
NHWK) (“NightHawk” or the “Company”), an integrated
contract development and manufacturing organization (CDMO), today
announced its Scorpius BioManufacturing subsidiary initiated its
first manufacturing run for a premier U.S.-based biopharmaceutical
company in the Company’s new, state-of-the-art microbial
manufacturing facility.
Jeff Wolf, CEO of NightHawk, commented, “We are
generating strong interest in our CDMO services, given our
state-of-the-art facility and the industry-wide lack of available
capacity for large molecule manufacturing. This demonstration run
in our new microbial facility marks a major milestone, as it
represents the first at-scale production run with a premier
biopharmaceutical company and reflects positively upon our
manufacturing readiness, as well as our ability to meet their
stringent product requirements. Importantly, this milestone enables
us to build upon the initial multi-million-dollar contract with
this client, which we expect to recognize as revenue during 2024.
We also look forward to further expanding our scope of work and
revenue potential of this agreement, as we work with our client to
submit the necessary regulatory filings to commence
commercial-scale production. We appreciate their trust in Scorpius
to ensure this important product gets to patients as safely and
quickly as possible.”
Mr. Wolf added, “This demonstration run and
expansion of this agreement is further validation of our recent
decision to streamline the organization through the divestiture of
non-core assets to double-down on our CDMO activities, which we
believe hold the potential to generate meaningful revenue and cash
flow. We are witnessing growing interest in the industry as we
build our track record and enhance our reputation. This is
reflected in our rapidly expanding sales pipeline that now includes
a number of premier biopharma companies, as well as leading
government and academic research institutes.”
NightHawk Biosciences,
Inc.NightHawk Biosciences, through its Scorpius
BioManufacturing subsidiary, is an integrated contract development
and manufacturing organization (CDMO) focused on rapidly advancing
biologic and cell therapy programs to the clinic and beyond.
Scorpius offers a broad array analytical testing, process
development, and manufacturing services to pharmaceutical and
biotech companies at its state-of-the art facilities in San
Antonio, TX. With an experienced team and new, purpose-built U.S.
facilities, Scorpius is dedicated to transparent collaboration and
flexible, high-quality biologics biomanufacturing. For more
information, please visit: www.nighthawkbio.com or
www.scorpiusbiologics.com, and also follow us on Twitter.
Forward Looking StatementThis
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions, and include statements such as recognizing revenue
from the agreement during 2024, expanding our scope of work and
revenue potential of this agreement and the CDMO activities holding
the potential to generate meaningful revenue and cash flow
Important factors that could cause actual results to differ
materially from current expectations include, among others, the
Company’s ability to generate future revenue from manufacturing
contracts booked in 2023 the Company’s ability to continue to grow
revenue, leverage fixed costs and achieve long-term profitability;
the Company’s ability to create substantial shareholder value as a
pure-play CDMO in an underserved marketplace; the Company’s
financing needs, its cash balance being sufficient to sustain
operations and its ability to raise capital when needed, the
Company’s ability to successfully operate as a CDMO, he continued
maintenance and growth of the Company’s and its subsidiaries’
patent estates the ability to obtain regulatory approval or to
comply with ongoing regulatory requirements, regulatory limitations
relating to the Company’s ability to successfully promote its
services and compete as a pure- play CDMO, and other factors
described in the Company’s annual report on Form 10-K for the year
ended December 31, 2022, subsequent quarterly reports on Form 10-Qs
and any other filings the Company makes with the SEC. The
information in this presentation is provided only as of the date
presented, and the Company undertakes no obligation to update any
forward-looking statements contained in this presentation on
account of new information, future events, or otherwise, except as
required by law.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017investorrelations@nighthawkbio.com
Nighthawk Biosciences (AMEX:NHWK)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Nighthawk Biosciences (AMEX:NHWK)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024